BOPI 03 BR/2023 REPERTOIRE NUMERIQUE 12 performed by a base station and corresponding embodiments of a base station are also disclosed. Fig. 9 Consulter le mémoire ________________________________________ (11) 20833 (51) A61K 31/375 (2018.01); A61K 31/454 (2018.01); A61K 31/56 (2018.01); A61P 11/06 (2018.01); A61P 37/00 (2018.01); A61P 37/08 (2018.01) (21) 1202100230 - PCT/RU2019/050225 (22) 22/11/2019 (30) RU n° 2018141291 du 23/11/2018 (54) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling. (72) NEBOLSIN, Vladimir Evgenievich (RU) (73) "CHEMIMMUNE THERAPEUTICS" LIMITED LIABILITY COMPANY, Skolkovo Innovation Centre, Bolshoj Blvd., 42, Building 1, 2nd floor, part of office 771, MOSCOW, 121205, Russian Federation (RU) (74) Cabinet BONNY & Associés, LAW FIRM, B.P. 869, YAOUNDE (CM). (57) The present invention relates to a medicine, in particular, to a new drug effective for the treatment of diseases associated with aberrant interferon gamma signaling, such as Sjogren's syndrome, dermatomyositis, systemic lupus erythematosus, or systemic sclerosis; for the treatment of patients suffering from cough; and for the treatment of disorders in steroid-resistant patients, such as asthma, rheumatoid arthritis, systemic lupus erythematosus, and gastrointestinal diseases, by administering a compound 1-(2-(1H-imidazol-4-yl)ethyl) piperidin2,6-dione. The invention provides the creation of a new effective drug for overcoming steroid resistance. Formula I
RkJQdWJsaXNoZXIy MTM1NDc3MA==